Perceptive Advisors is a life sciences investment manager registered with the SEC as an investment adviser (CRD 154703, SEC registration effective 4 October 2010). It says it runs four strategies. The Perceptive Life Sciences Fund invests globally in public and private companies developing biotechnology products, drugs, medical devices and diagnostics, with the majority of investments in publicly traded small and mid cap companies, and participates in growth rounds, crossover rounds, IPOs and public follow-ons. Credit Opportunities, launched with its first closed-end fund in 2014, lends to healthcare companies across biopharma, medical devices, diagnostics, digital health, women's health, life sciences research and healthcare IT, and states a range of $20M to $300M per investment and approximately $3.5B of capital raised for private credit. Capital Solutions provides structured capital to later-stage and commercial-stage life sciences companies. The venture strategy, run through the Perceptive Xontogeny Venture Funds, invests primarily at seed and Series A in biotechnology, medtech, healthtech, digital health and healthcare tools and services, states investments of $10M to $50M when leading or co-leading a Series A, states over $700M across its venture funds, and says its people take board seats. The firm describes its team as scientists, technologists, molecular biologists, MDs and PhDs.
Approximately $11B (across its strategies as of 30 June 2026, per the firm's own About page; the firm's Form ADV Item 5.F figure could not be read) AUM82/100 Power Score™1999 FoundedNew York, NY
BiotechLife SciencesMedical DevicesDiagnosticsDigital HealthHealthcare IT
Joseph Edelman founds Perceptive Advisors in New York as a hedge fund specialising in biotechnology stocks.
2010
SEC registration as an investment adviser becomes effective on 4 October 2010 (CRD 154703, SEC file 801-71841).
2014
The firm launches its Credit Opportunities strategy with its first closed-end credit fund.
2018
Perceptive Xontogeny Venture Fund, LP is established.
2021
Perceptive Xontogeny Venture Fund II, LP closes.
2024
Perceptive Capital Solutions Corp, a special purpose acquisition company, completes its IPO (Form 424B4 filed 12 June 2024).
2026
Perceptive Capital Solutions Corp is renamed Freenome, Inc. on 15 July 2026 following its business combination with Freenome Holdings, and trades on Nasdaq as FRNM.